SJStefanie Jaskulski

Stefanie Jaskulski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefanie Jaskulski has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Depression and anxiety symptoms in internally migrated women and men after the German unification: Baseline results from the German National Cohort Study (NAKO)

    by D. Otten, C. Kasinger, L. Kriechel, A.N. Tibubos, K. Berger, G. Schomerus, T. McLaren, M.E. Beutel, S. Speerforck, E. Brähler, et al.

  • Prognostic associations of circulating phytoestrogens and biomarker changes in long-term survivors of postmenopausal breast cancer

    by Stefanie Jaskulski, Audrey Y. Jung, Marianne Huebner, Gernot Poschet, Rüdiger Hell, Anika Hüsing, Sandra Gonzalez-Maldonado, Sabine Behrens, Nadia Obi, Heiko Becher, et al.

    Lignans are associated with improved postmenopausal breast cancer (BC) survival, but whether these associations, particularly with enterolactone (major lignan metabolite), persist over time is unclear. Little is known about other phytoestrogens on prognosis in long-term survivors. The study examines associations of prognosis with 1) circulating postdiagnosis enterolactone, 2) eight circulating phytoestrogen metabolites, and 3) changes in enterolactone and genistein. In a German cohort of 2,105 postmenopausal BC patients with blood samples collected at recruitment 2002–2005 (baseline) and re-interview in 2009 (follow-up), delay-entry Cox proportional hazards regression was used. Landmark analysis showed that circulating enterolactone (log2) associations with 5-year survival changed over time, with strongest hazard ratios of 0.89 (95% CI, 0.80–0.99) at blood draw (BD) and 0.86 (0.77–0.97) at 2 years post-BD for BC mortality, and 0.87 (0.80–0.95) at BD and 0.84 (0.76–0.92) at 3 years post-BD for all-cause mortality, which attenuated thereafter. In long-term survivors, increasing concentrations of genistein (1.17, 1.01–1.36), resveratrol (1.19, 1.02–1.40), and luteolin (1.96, 1.07–3.58) measured in follow-up blood samples were associated with poorer subsequent prognosis. Neither enterolactone at follow-up nor changes in enterolactone/genistein were associated with prognosis. Large long-term longitudinal studies with multiple phytoestrogen measurements are required to understand long-term effects of phytoestrogens after BC.


  • Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy

    by Audrey Y Jung, Xinting Cai, Kathrin Thoene, Nadia Obi, Stefanie Jaskulski, Sabine Behrens, Dieter Flesch-Janys, Jenny Chang-Claude

    There is a paucity of information on the prevalence of dietary supplement use in breast cancer survivors. Only a few studies have examined the impact of dietary supplements, particularly antioxidants, on breast cancer prognosis and the results are inconclusive. We examined pre- and postdiagnosis use of supplements in postmenopausal breast cancer survivors in Germany and investigated associations between postdiagnosis use of antioxidants and other supplements, and prognosis (total and breast cancer mortality, and recurrence-free survival) both overall and in women who received chemotherapy and radiation therapy. Data from 2223 postmenopausal women diagnosed with nonmetastatic breast cancer from the population-based Mamma Carcinoma Risk Factor Investigation (MARIE) study were used. Women were interviewed at recruitment in 2002-2005 and again in 2009 and followed-up until 30 June 2015. Multivariate Cox regression analysis was used to estimate HRs and corresponding 95% CIs. Pre- and postdiagnosis supplement use was reported by 36% and 45% of the women, respectively. There were 240 deaths (134 from breast cancer) and 200 breast cancer recurrences after a median follow-up time of 6.0 y after the 2009 re-interview. After adjusting for relevant confounders, concurrent antioxidant use with chemotherapy or radiation therapy among 1940 women was associated with increased risk of total mortality (HR: 1.64; 95% CI: 1.01, 2.66) and worsened recurrence-free survival (HR: 1.84; 95% CI: 1.26, 2.68). Overall postdiagnosis supplement use was not associated with breast cancer prognosis. Antioxidant use during chemotherapy or radiation therapy was associated with worsened breast cancer prognosis in postmenopausal women. There was no overall association between postdiagnosis supplement use and breast cancer prognosis. Results from our study align with the current recommendation to possibly avoid the use of antioxidants during chemotherapy or radiation therapy.


  • Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers

    by Stefanie Jaskulski, Audrey Y. Jung, Sabine Behrens, Theron Johnson, Rudolf Kaaks, Kathrin Thöne, Dieter Flesch‐Janys, Disorn Sookthai, Jenny Chang‐Claude

    Higher lignan exposure has been associated with lower all‐cause mortality (ACM) and breast cancer‐specific mortality (BCSM) for postmenopausal breast cancer patients. However, the biological mechanisms underpinning these associations are still unclear. We investigated for the first time whether and to what extent the association between enterolactone (ENL), the major lignan metabolite, and postmenopausal breast cancer prognosis is mediated by inflammatory biomarkers. Circulating concentrations of ENL and inflammatory markers were measured in a population‐based prospective cohort of 1,743 breast cancer patients recruited between 2002 and 2005 and followed‐up until 2009. Hazard ratios (HR) and 95% CIs were estimated using multivariable Cox regression. Mediation analysis was performed to estimate the percentage association between ENL (log2) and ACM, BCSM and distant disease‐free survival (DDFS), which is mediated by C‐reactive protein (CRP) (log2), as the strongest potential mediator, and also interleukin (IL)‐10. Median serum/plasma ENL and CRP concentrations for all patients, including 180 deceased patients, were 23.2 and 17.5 nmol/L, and 3.2 and 6.5 mg/l, respectively. ENL concentrations were significantly inversely associated with ACM, BCSM and DDFS (per doubling of ENL concentrations: HRs 0.93 [0.87, 0.99], 0.91 [0.84, 0.99] and 0.92 [0.87, 0.99]), after adjusting for prognostic factors and BMI. Estimated 18, 14 and 12% of the effects of ENL on ACM, BCSM and DDFS, respectively, were mediated through CRP. No mediational effect of IL‐10 was found. We provide first evidence that the proinflammatory marker CRP may partially mediate the association of ENL with postmenopausal breast cancer survival, which supports hormone‐independent mechanisms.


  • Genistein and enterolactone in relation to Ki‐67 expression and HER2 status in postmenopausal breast cancer patients

    by Stefanie Jaskulski, Audrey Y. Jung, Anja Rudolph, Theron Johnson, Kathrin Thöne, Esther Herpel, Peter Sinn, Jenny Chang‐Claude

    Scope: Phytoestrogens (PE) may improve breast cancer prognosis by modifying tumor prognostic markers, such as cell proliferation marker Ki‐67 and human epidermal growth factor receptor 2 (HER2). Epidemiological evidence linking lignans and isoflavones to Ki‐67 and HER2 is limited. We examined associations between the major metabolites of lignans and isoflavones – enterolactone (ENL) and genistein (GEN) – respectively, and Ki‐67 expression and HER2 in tumor tissue of breast cancer patients.Methods and results: Data from 1060 invasive breast cancer patients from the population‐based MARIE study were used. Multivariate‐adjusted linear (Ki‐67 log‐transformed) and quantile regression, and logistic regression analyses (HER2, Ki‐67 dichotomized) were performed to calculate β estimates and ORs, respectively. Median post‐diagnostic ENL and GEN concentrations were 19.5 and 4.8 nmol/L, respectively. Median Ki‐67 was 12.0%, and 21.2% of the tumors were HER2+. After adjustment, there was an inverse association between GEN and Ki‐67 at high expression levels (OR for Ki‐67 ≥20% versus <20% of 0.93 (95%CI [0.87;0.99]) per 10 nmol/L GEN increment).Conclusion: Our findings indicate an inverse association between GEN and Ki‐67 at high levels of Ki‐67 expression. Additional investigations are recommended to confirm our findings and to further elucidate mechanisms linking PE metabolites to breast cancer survival.